首页> 外文期刊>American journal of clinical pathology. >Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens.
【24h】

Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens.

机译:免疫组化和组织化学研究在细胞学标本中对肺腺癌和鳞状细胞癌分类的有用性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Histologic subtyping of non-small cell lung carcinoma (NSCLC) is important because the efficacy of new treatments depends on tumor histologic features. We assessed the diagnostic accuracy of classification of lung adenocarcinoma and squamous cell carcinoma (SCC) on cytologic and biopsy specimens based on cytomorphologic studies alone or in combination with ancillary studies compared with resection specimens. Compared with adenocarcinoma, the diagnosis of SCC was based more often on cytomorphologic studies alone (139/185 [75.1%] vs 107/263 [40.7%]). Significantly increased use of immunohistochemical studies in cytology was noted after introduction of targeted lung carcinoma therapies (22/156 [14.1%] for adenocarcinoma and 5/46 [11%] for SCC from 2000-2004 vs 134/156 [85.9%] for adenocarcinoma and 41/46 [89%] for SCC from 2005-2010). Use of immunohistochemical studies resulted in increased diagnostic accuracy for adenocarcinoma (56% [44/78] from 2000-2004 vs 83.2% [154/185] after 2005) but not for SCC (77% [57/74] before 2004 vs 73.9% [82/111] from 2005-2010). Adenocarcinoma showed high expression of cytokeratin (CK)7 (146/146 [100%]), thyroid transcription factor-1 (131/152 [86.2%]), surfactant A (29/36 [81%]), and periodic acid-Schiff with diastase (69/86 [80%]). All SCCs were positive for CK5/6 and p63. Use of immunohistochemical studies on cytologic cell blocks may improve classification of NSCLC.
机译:非小细胞肺癌(NSCLC)的组织学亚型很重要,因为新疗法的疗效取决于肿瘤的组织学特征。我们根据单独的细胞形态学研究或与切除标本相结合的辅助研究,评估了细胞学和活检标本对肺腺癌和鳞状细胞癌(SCC)分类的诊断准确性。与腺癌相比,SCC的诊断更多地基于细胞形态学研究(139/185 [75.1%] vs 107/263 [40.7%])。在引入靶向性肺癌治疗后,注意到细胞学中免疫组化研究的使用显着增加(2000年至2004年,腺癌为22/156 [14.1%],SCC为5/46 [11%],而134/156 [85.9%])腺癌,2005-2010年间SCC占41/46 [89%]。免疫组化研究的使用提高了腺癌的诊断准确性(2000-2004年为56%[44/78],而2005年之后为83.2%[154/185]),但对SCC却没有(诊断前的准确性(2004年之前为77%[57/74]),对73.9 %[82/111] from 2005-2010)。腺癌显示出高表达的细胞角蛋白(CK)7(146/146 [100%]),甲状腺转录因子-1(131/152 [86.2%]),表面活性剂A(29/36 [81%])和高碘酸-带有舒张酶的席夫(69/86 [80%])。所有SCC CK5 / 6和p63均为阳性。对细胞学细胞块进行免疫组织化学研究可改善NSCLC的分类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号